Chickenpox vaccination lowers risk of pediatric shingles
Kaiser Permanente-led study of more than 6 million children showed routine varicella vaccine considerably lessened likelihood of painful shingles disease
Oakland, Calif. – Children who receive the chickenpox (varicella) vaccine are significantly less likely to contract shingles, according to a new study led by researchers at the Kaiser Permanente Center for Health Research published today in the journal Pediatrics.
Shingles, or herpes zoster, is caused by the varicella-zoster virus, the same virus that causes chickenpox. According to the Centers for Disease Control and Prevention, there are an estimated 1 million cases of HZ each year in the United States. However, pediatric HZ is a rare disease, and the symptoms are usually milder for children compared with adults, who typically report a painful, burning, and blistering skin rash.
“Since the introduction of the chickenpox vaccine, we have known how effective it is in preventing children from contracting that itchy and painful disease, but we set out to determine if the vaccine would also reduce risk of herpes zoster,” explained lead investigator Sheila Weinmann, PhD. “Our findings demonstrate that the vaccine does reduce the likelihood of shingles in kids, highlighting the dual benefits of the chickenpox vaccine.”
The study, funded by the CDC, looked at the electronic health records of more than 6.3 million children between 2003 and 2014, using data from 6 integrated health care organizations. Approximately 50% of the children were vaccinated for some or all of the study period.
Researchers found that, overall, HZ risk is much lower in vaccinated than unvaccinated children. Specifically, they concluded the following:
- Over the 12-year period of the study, the rate of pediatric HZ declined by 72% overall as the number of vaccinated children rose.
- Incidence of HZ was 78% lower in vaccinated children than in unvaccinated children.
- Rates for immunosuppressed children, who were unable to receive the vaccination, were 5- to 6-times higher than for those who were not immunosuppressed.
“We looked at the incidence rates of HZ overall, at how many cases there were per 100,000 person-years, including by age and gender,” noted Weinmann. Person-years refers to the type of measurement that takes into account both the number of children who were included in the HZ study and the amount of time each child spent in the study over its 12-year course. “We saw the highest rates of HZ in the early years of the study when there was a higher proportion of children, particularly older children, who had not received the varicella vaccine.”
The rate of HZ among children who were unvaccinated climbed from 2003 to 2007 and then declined sharply through the end of the study period. Increasing rates of vaccination over the study period reduced the risk of contracting HZ overall for all children, including those who were unvaccinated. The decline could also have been related to the introduction of the second vaccine dose beginning in 2007, as HZ incidence was much lower in those children who received the 2-dose vaccinations rather than 1-dose vaccination.
The research team included Sheila Weinmann, PhD; Allison L. Naleway, PhD; Padma Koppolu, MPH; Stephanie A. Irving, MHS; Elizabeth Liles, MD; and Ning Smith, PhD, of the Kaiser Permanente Center for Health Research; Roger Baxter, MD, and Nicola P. Klein, MD, PhD, of the Vaccine Study Center, Kaiser Permanente Northern California; Edward A. Belongia, MD, of the Marshfield Clinic Research Institute, Marshfield, Wisconsin; Simon J. Hambidge, MD, PhD, of Denver Health, Denver, Colorado; Michael L. Jackson, PhD, of Kaiser Permanente Washington; Bruno Lewin, MD, of Kaiser Permanente Southern California; Mona Marin, MD, and Eric Weintraub, MPH, of the Centers for Disease Control and Prevention; and Colleen Chun, MD, of the Division of Pediatric Infectious Diseases, Department of Pediatrics, Kaiser Permanente Northwest.
About Kaiser Permanente
Kaiser Permanente is committed to helping shape the future of health care. We are recognized as one of America’s leading health care providers and not-for-profit health plans. Founded in 1945, Kaiser Permanente has a mission to provide high-quality, affordable health care services and to improve the health of our members and the communities we serve. We currently serve more than 12.3 million members in eight states and the District of Columbia. Care for members and patients is focused on their total health and guided by their personal Permanente Medical Group physicians, specialists and team of caregivers. Our expert and caring medical teams are empowered and supported by industry-leading technology advances and tools for health promotion, disease prevention, state-of-the-art care delivery and world-class chronic disease management. Kaiser Permanente is dedicated to care innovations, clinical research, health education and the support of community health.